Antifibrotic therapy for Lower Urinary Tract Symptoms secondary to Benign Prostatic Hyperplasia
Ajinkya R. Limkar, Kevin T. McVary, William A. Ricke, Matthew S. Lee · 2026
Read Antifibrotic therapy for Lower Urinary Tract Symptoms secondary to Benign Prostatic Hyperplasia by Ajinkya R. Limkar, Kevin T. McVary, William A. Ricke, Matthew S. Lee (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13482506.txt.
Description
Ajinkya Limkar and three colleagues reviewed in 2026 antifibrotic therapy for urinary symptoms from benign prostate enlargement. Over half of men past 50 live with these symptoms, yet drug innovation for the condition has stalled.
Searching PubMed and ClinicalTrials.gov, they covered molecular, translational, and clinical work and built the case that prostate fibrosis helps drive symptoms. No antifibrotic drug is yet in use for this purpose, leaving fibrosis-driven symptoms untreated, though candidates exist for men who progress on current drugs. The review also sketches diagnostic studies that could spot fibrosis-driven cases for future trials.
Catalog record
| CREATOR | Ajinkya R. Limkar, Kevin T. McVary, William A. Ricke, Matthew S. Lee |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |